Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 17

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 17
---
 In addition, we may face additional risks and uncertainties not currently known to us, or which as of the date of this registration statement we might not consider significant, which may adversely affect our business. If any of the following risks occur, our business, financial condition and results of operations could be materially adversely affected. In such a case, the trading price of our Common Stock could decline due to any of these risks or uncertainties, and you may lose part or all of your investment.

<div align='center'>RISK FACTOR SUMMARY</div>

The following is a summary
of the principal risks that could adversely affect our business, operations, and financial results. A more thorough discussion of these
and other risks are listed under the section entitled “Risk Factors” commencing on page 5.

Risks Relating to the Company’s Business and Financial Position

| ● | The Company has had                                                                                                                       
 no revenue and has incurred significant operating losses since inception and is expected to continue to incur significant operating       
 losses for the foreseeable future. As an R&D-stage company, we are focused on advancing our pipeline, and our ability to achieve          
 profitability will depend on the successful development and potential commercialization of one or more of our product candidates.         |
| ● | The Company has a limited                                                                                                                 
 operating history as a research and development-stage company, which may make it difficult to evaluate the prospects for the Company’s    
 future viability.                                                                                                                         |
| ● | We may not realize the                                                                                                                    
 anticipated benefits of the Share Exchange and succeeding to business of LipoVation.                                                      |
| ● | Failure to comply with LipoVation’s                                                                                                       
 contractual obligations under the Yissum License Agreements or other licenses or related agreements to which we may be a party in         
 the future may result in the loss of license rights that may be necessary for developing our on the NLP-based medicines based therapeutic 
 products.                                                                                                                                 |
| ● | If we are unable to manage                                                                                                                
 our growth and expand our operations successfully, our reputation, brands, business and results of operations may be harmed.              |
| ● | The Company will need additional                                                                                                          
 funding and it may not be available to us on acceptable terms. If the Company is unable to raise capital when needed, it could be         
 forced to delay, reduce or eliminate its product development programs or commercialization efforts.                                       |
| ● | We face competition from                                                                                                                  
 other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.